Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

The planned length of participation in the study for each participant was up to approximately 110 weeks (from screening through completion of follow-up). This included: * Screening/baseline period of up to 4 weeks * Double-blind, placebo-controlled treatment period of 48 weeks * Open-label extension treatment period of 48 weeks (all participant to enter a 48-week open label extension period and receive active treatment with lademirsen \[SAR339375\]). * Post-treatment follow-up period of 10 weeks.